Emerson Electric
EMR
$130.65
-1.19%
Emerson Electric Co. is a leading global industrial automation company, providing a wide range of automation software, hardware, and power tools for manufacturing and process industries. The company has solidified its identity as a pure-play automation leader following the strategic divestiture of its climate technology and consumer businesses. The current investor narrative centers on the company's strategic pivot and its positioning to capitalize on the long-term secular trends of factory automation, digital transformation, and reshoring, though recent stock price volatility reflects market concerns over cyclical industrial demand and execution of its focused strategy.…
EMR
Emerson Electric
$130.65
Investment Opinion: Should I buy EMR Today?
Rating & Thesis: Hold. Emerson is a fundamentally sound company caught in a negative momentum cycle; investors should wait for evidence of stabilization in both technicals and fundamentals before committing new capital. The mixed analyst sentiment, with recent downgrades, supports a cautious stance.
Supporting Evidence: The recommendation is backed by four key data points: 1) A reasonable forward P/E of 18.59x based on expected EPS growth to $9.16, 2) Robust TTM free cash flow of $2.575 billion supporting shareholder returns, 3) Solid profitability metrics including an 11.31% ROE and a 13.92% net margin, and 4) A strategic position in the secular growth market of industrial automation. However, these are offset by a high trailing P/E of 32.20x and a technical breakdown showing a -10.18% 3-month return.
Risks & Conditions: The two biggest risks are a further deterioration in industrial demand, compressing revenue and margins, and a loss of investor confidence leading to continued multiple compression. This Hold would upgrade to a Buy if the stock finds support above its 52-week low and the forward P/E compresses further toward 16x on sustained earnings growth, or if Q2 results show a rebound in gross margins above 50%. It would downgrade to a Sell if revenue growth turns negative YoY or if the stock breaks decisively below the $114.83 support level. Relative to its own history, the stock appears fairly valued to slightly overvalued on a trailing basis, but undervalued on forward earnings if growth materializes.
Sign up to view all
EMR 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While Emerson's strong cash flow generation and strategic positioning are foundational strengths, the near-term outlook is clouded by technical breakdown, margin pressure, and analyst uncertainty. The stock is likely to remain range-bound until there is clarity on the industrial cycle and the company's ability to defend profitability. The stance would upgrade to bullish on a confirmed technical reversal above $150 coupled with margin stabilization, or downgrade to bearish on a breakdown below $115 with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $169.85 and implied upside of +30.0% versus the current price.
Average Target
$169.85
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$105 - $170
Analyst target range
The stock is covered by 10 analysts, indicating solid institutional interest. The consensus sentiment appears neutral to cautiously optimistic, with recent actions from firms like Deutsche Bank downgrading from 'Buy' to 'Hold' and Oppenheimer moving from 'Outperform' to 'Perform', while others like Citigroup and UBS maintain or initiated 'Buy' ratings. The average target price and explicit Buy/Hold/Sell distribution are not provided in the data, preventing a calculation of implied upside/downside to consensus. The target price range is also not specified, so the assumptions behind high and low targets cannot be detailed. The available institutional ratings show a pattern of stabilization in early 2026 after some downgrades, with the most recent actions in February 2026 including reiterations of 'Equal Weight' and 'Outperform'. The lack of a clear, unified bullish consensus and the presence of downgrades signal that analysts are grappling with the near-term outlook amidst the stock's technical breakdown, leading to higher uncertainty reflected in the recent price volatility.
Bulls vs Bears: EMR Investment Factors
The evidence currently tilts bearish, primarily due to severe technical deterioration, elevated trailing valuation, and analyst downgrades that have created a negative near-term momentum cycle. However, strong underlying fundamentals—including robust free cash flow, solid profitability, and a strategic focus on automation—provide a counterweight. The single most important tension in the investment debate is whether the current price decline represents a cyclical overshoot creating a buying opportunity for a high-quality industrial, or the beginning of a fundamental derating as growth expectations fail to materialize. The resolution hinges on whether Q1's margin pressure and revenue softness are transitory or indicative of a more persistent downturn.
Bullish
- Strong Free Cash Flow Generation: Emerson generates robust free cash flow, with trailing twelve-month FCF of $2.575 billion. This provides significant financial flexibility to fund growth, maintain its dividend (51.98% payout ratio), and execute share repurchases without straining the balance sheet.
- Solid Profitability and Capital Efficiency: The company maintains healthy profitability with a Q1 net margin of 13.92% and a Return on Equity of 11.31%. Its moderate debt-to-equity ratio of 0.678 indicates a conservatively managed balance sheet, supporting sustainable growth.
- Attractive Forward Valuation: The forward P/E of 18.59x is significantly lower than the trailing P/E of 32.20x, implying the market expects strong earnings growth. This forward multiple is based on analyst EPS estimates averaging $9.16, suggesting a reasonable valuation for a pure-play automation leader.
- Strategic Focus on High-Growth Automation: Following divestitures, Emerson is now a pure-play industrial automation company, positioned to capitalize on secular trends like digital transformation and reshoring. Its Intelligent Devices segment, contributing $2.39 billion in Q1 revenue, is the primary growth engine.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is in a pronounced downtrend, down 10.18% over 3 months and 5.24% over 1 month, severely underperforming the S&P 500 by -18.60% and -10.84% respectively. Trading at $133.05, it is just 19.5% above its 52-week low, signaling weak momentum and potential oversold conditions.
- Elevated Trailing Valuation and Margin Pressure: The trailing P/E of 32.20x is elevated and sits above the median of its recent historical range. Concurrently, Q1 gross margin of 48.56% shows pressure compared to the TTM gross margin of 52.85%, indicating potential profitability challenges.
- Analyst Uncertainty and Recent Downgrades: Analyst sentiment is mixed, with recent actions including downgrades from Deutsche Bank (Buy to Hold) and Oppenheimer (Outperform to Perform). This lack of a unified bullish consensus reflects heightened uncertainty about the near-term outlook amidst the stock's breakdown.
- Cyclical Revenue Softening and High Beta: Q1 revenue of $4.345 billion represents a sequential decline from Q4's $4.855 billion, suggesting near-term cyclical headwinds. The stock's beta of 1.255 means it is 26% more volatile than the market, amplifying downside risk during sector-wide sell-offs.
EMR Technical Analysis
The stock is in a pronounced downtrend, having declined 10.18% over the past three months and 5.24% over the past month, significantly underperforming the S&P 500 which gained 8.42% and 5.6% over the same periods, respectively. Currently trading at $133.05, the price sits just 19.5% above its 52-week low of $114.83 and a substantial 19.5% below its 52-week high of $165.15, indicating it is trading in the lower quartile of its annual range and signaling weak momentum and potential oversold conditions. Recent momentum is decisively negative, with the 1-month decline of 5.24% accelerating the 3-month loss of 10.18%, and both periods showing severe relative weakness against the market of -10.84% and -18.60%, respectively. This sharp sell-off diverges from a still-positive 1-year return of 10.64%, suggesting a breakdown from a longer-term consolidation phase, potentially driven by sector rotation or fundamental concerns. Key technical levels are clearly defined, with immediate support at the 52-week low of $114.83 and formidable resistance at the 52-week high of $165.15. A breakdown below $114.83 would signal a continuation of the bearish trend, while a recovery above $165.15 would require a significant catalyst. The stock's beta of 1.255 confirms it is approximately 26% more volatile than the broader market, which amplifies both downside risk and potential upside during recoveries, a critical factor for risk-adjusted positioning.
Beta
1.25
1.25x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$115-$165
Price range past year
Annual Return
+9.3%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | -10.7% | +3.3% |
| 3m | -13.6% | +6.9% |
| 6m | +5.6% | +12.4% |
| 1y | +9.3% | +23.4% |
| ytd | -3.8% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Revenue growth has been modest but positive, with Q1 2026 revenue of $4.345 billion representing a 4.07% year-over-year increase. Segment data shows the Intelligent Devices segment is the primary driver, contributing $2.39 billion, followed by Software and Systems at $1.453 billion and Safety and Productivity at $503 million. However, sequential trends from recent quarters show revenue has softened from the $4.855 billion reported in Q4 2025, indicating potential near-term cyclical headwinds or normalization post-divestitures. The company remains solidly profitable, reporting Q1 2026 net income of $605 million and a net margin of 13.92%. Gross margin for the quarter was 48.56%, which is healthy though down from the 52.85% trailing twelve-month gross margin indicated in valuation data, suggesting some quarterly margin pressure. Profitability metrics are stable, with Return on Equity (ROE) at 11.31% and Return on Assets (ROA) at 6.68%, reflecting efficient use of capital. The balance sheet is conservatively managed with a debt-to-equity ratio of 0.678, indicating a moderate level of financial leverage. Liquidity is adequate with a current ratio of 0.876, and the company generates robust cash flow, evidenced by trailing twelve-month free cash flow of $2.575 billion. This strong FCF generation provides ample capacity for funding growth initiatives, dividends (payout ratio of 51.98%), and share repurchases without over-reliance on external financing.
Quarterly Revenue
$4.3B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.48%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given a positive net income of $605 million, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 32.20x, while the forward PE is significantly lower at 18.59x, implying the market expects a substantial 42% growth in earnings over the next year, aligning with analyst EPS estimates averaging $9.16. Compared to industry averages, Emerson's valuation presents a mixed picture; its forward PE of 18.59x is not explicitly compared in the data, but its Price-to-Sales (PS) ratio of 4.10x and EV/EBITDA of 17.78x are key benchmarks. The stock's premium or discount to sector peers cannot be quantified precisely without provided industry average multiples, but the current multiples suggest the market is pricing in its leadership position and growth expectations from automation. Historically, the stock's own trailing PE has fluctuated significantly, ranging from a low near 15.7x in late 2024 to a high of 97.8x in early 2024, with the current 32.20x sitting above the median of its recent historical range. This positioning near the higher end of its own historical band suggests that while the stock has corrected in price, valuation compression has been limited, and the market still embeds relatively optimistic expectations for future earnings growth and margin expansion.
PE
32.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Emerson faces near-term margin pressure, with Q1 gross margin contracting to 48.56% from a TTM level of 52.85%. While the balance sheet is conservative with a 0.678 debt-to-equity ratio, the company's revenue has shown sequential softening, declining from $4.855 billion in Q4 to $4.345 billion in Q1, indicating vulnerability to industrial cyclicality. Its dividend payout ratio of 51.98% is sustainable but relies on continued strong free cash flow generation, which could be pressured if earnings growth stalls.
Market & Competitive Risks: The stock trades at a premium trailing P/E of 32.20x, which is elevated relative to its own historical median, creating valuation compression risk if growth expectations moderate. With a beta of 1.255, the stock is 26% more volatile than the market, making it highly sensitive to broader market downturns and sector rotation out of industrials. Recent analyst downgrades signal growing concerns about execution and near-term demand, which could lead to further multiple contraction if the negative sentiment persists.
Worst-Case Scenario: A severe industrial recession, coupled with execution missteps in its focused automation strategy, could trigger a simultaneous earnings miss and multiple compression. In this scenario, the stock could re-test its 52-week low of $114.83, representing a downside of approximately -14% from the current price of $133.05. A break below this level could see the stock fall toward the $105-$110 range, aligning with a historical max drawdown of -23.74%, implying a potential total loss of up to -21% from current levels.
FAQ
The key risks, ranked by severity, are: 1) Cyclical Demand Risk: Sequential revenue decline from $4.855B to $4.345B indicates sensitivity to industrial cycles. 2) Valuation Compression Risk: The high trailing P/E of 32.20x could contract sharply if growth slows. 3) Execution & Sentiment Risk: Recent analyst downgrades reflect uncertainty about the company's focused strategy post-divestitures. 4) Market Volatility Risk: With a beta of 1.255, the stock will likely fall more than the market in a downturn, as evidenced by its -18.60% relative performance over 3 months.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (55% probability) sees the stock trading between $140 and $155 as growth stabilizes. The Bull Case (25% probability) could drive the stock to $165-$175 on strong execution and margin recovery. The Bear Case (20% probability) risks a decline to $115-$125 if the industrial slowdown worsens. The most likely scenario is the Base Case, which assumes the company meets consensus EPS estimates of ~$9.16 but struggles to re-rate its multiple significantly higher amid a cautious macro environment.
EMR's valuation is a tale of two multiples. On a trailing basis, it appears overvalued with a P/E of 32.20x, which is above the median of its own recent historical range. However, its forward P/E of 18.59x, based on expected EPS of $9.16, suggests the market is pricing in significant growth and the stock could be fairly valued or even undervalued if those expectations are met. The key is whether the company can deliver the implied 42% earnings growth to justify the forward multiple. Currently, the market is paying a premium for future growth, making the stock fairly valued on forward estimates but rich on trailing results.
EMR is a Hold, not a clear-cut buy at current levels. For value-oriented investors seeking a high-quality industrial with a strong balance sheet and robust free cash flow, any further weakness toward the $120-$125 range could present an attractive entry point. However, given the stock's severe underperformance (-10.18% over 3 months), elevated trailing P/E of 32.20x, and recent analyst downgrades, it is prudent to wait for evidence of fundamental stabilization. It is a good buy for long-term investors only if they are comfortable with near-term volatility and believe the automation thesis will overcome cyclical headwinds.
EMR is primarily suitable for a long-term investment horizon of 3-5 years. Its high beta of 1.255 and recent severe volatility make it a poor candidate for short-term trading. The investment thesis is based on the long-term secular growth of industrial automation, which will take multiple years to fully play out. The company's stable dividend (1.61% yield) and share repurchase program also reward patient holders. A minimum holding period of 18-24 months is suggested to ride out near-term cyclicality and allow the strategic pivot to bear fruit.